10. August 2011 12:03
NICE wants further information on Roche’s RoActemra (tocilizumab) for the treatment of systemic juvenile idiopathic arthritis (JIA) after failing to recommend it in draft guidance.
The Institute’s independent Appraisal Committee has requested a range of detailed information including comparison data to existing treatments and a revised model.
Professor Carole Longson, Health Technology Evaluation Centre Director at NICE, says more information is required so NICE can “fully assess the benefits that tocilizumab might provide”.
A public consultation has now been opened with responses welcomed until 1st September.
The appraisal focused on young people aged two years and older with JIA where specific previous treatments have not produced an adequate response.
But NICE says further data is required on RoActemra when it’s used in treating systemic JIA where the individual’s condition has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate. Information about joint damage for patients receiving RoActemra, including long-term follow-up, has also been requested.
The draft guidance also does not recommend the treatment where methotrexate has not yet been tried, but NSAIDs and systemic corticosteroids have already been used.
“In the meantime, we welcome comments from patients and their carers and families, and clinicians, as part of our public consultation on the Committee’s provisional recommendations,” said Professor Longson.